IL100765A - תרכיב נגד שפעת נגיפית עם השפעה סינרגית המכיל כתוספת ליבת הנגיף של שפעת - Google Patents

תרכיב נגד שפעת נגיפית עם השפעה סינרגית המכיל כתוספת ליבת הנגיף של שפעת

Info

Publication number
IL100765A
IL100765A IL10076592A IL10076592A IL100765A IL 100765 A IL100765 A IL 100765A IL 10076592 A IL10076592 A IL 10076592A IL 10076592 A IL10076592 A IL 10076592A IL 100765 A IL100765 A IL 100765A
Authority
IL
Israel
Prior art keywords
core
vaccine
protein
additive
composition according
Prior art date
Application number
IL10076592A
Other languages
English (en)
Other versions
IL100765A0 (en
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9409015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL100765(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of IL100765A0 publication Critical patent/IL100765A0/xx
Publication of IL100765A publication Critical patent/IL100765A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL10076592A 1991-01-24 1992-01-24 תרכיב נגד שפעת נגיפית עם השפעה סינרגית המכיל כתוספת ליבת הנגיף של שפעת IL100765A (he)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9100806A FR2671974A1 (fr) 1991-01-24 1991-01-24 Composition vaccinale contre la grippe, a effet synergique, contenant comme additif du core de virus grippal.

Publications (2)

Publication Number Publication Date
IL100765A0 IL100765A0 (en) 1992-09-06
IL100765A true IL100765A (he) 1996-06-18

Family

ID=9409015

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10076592A IL100765A (he) 1991-01-24 1992-01-24 תרכיב נגד שפעת נגיפית עם השפעה סינרגית המכיל כתוספת ליבת הנגיף של שפעת

Country Status (10)

Country Link
EP (1) EP0522138B2 (he)
AT (1) ATE234861T1 (he)
AU (1) AU654699B2 (he)
CA (1) CA2078985C (he)
DE (1) DE69232962T3 (he)
FR (1) FR2671974A1 (he)
IL (1) IL100765A (he)
NZ (1) NZ241398A (he)
WO (1) WO1992013002A1 (he)
ZA (1) ZA92510B (he)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
FR2723740B1 (fr) * 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
WO1998046262A1 (en) * 1997-04-16 1998-10-22 Connaught Laboratories, Inc. Anti-influenza compositions supplemented with neuraminidase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2483779A1 (fr) * 1980-06-05 1981-12-11 Synthelabo Procede pour isoler des antigenes glycoproteiques viraux et son application a la preparation de vaccins
GB8502096D0 (en) * 1985-01-28 1985-02-27 Medical Res Council Influenza vaccine
US5136019A (en) * 1989-05-24 1992-08-04 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use

Also Published As

Publication number Publication date
AU654699B2 (en) 1994-11-17
EP0522138B2 (fr) 2007-02-14
CA2078985A1 (fr) 1992-07-25
DE69232962T2 (de) 2005-06-23
FR2671974B1 (he) 1995-03-03
NZ241398A (en) 1994-08-26
ATE234861T1 (de) 2003-04-15
DE69232962T3 (de) 2007-11-08
EP0522138A1 (fr) 1993-01-13
WO1992013002A1 (fr) 1992-08-06
IL100765A0 (en) 1992-09-06
ZA92510B (en) 1992-11-25
FR2671974A1 (fr) 1992-07-31
DE69232962D1 (de) 2003-04-24
AU1248792A (en) 1992-08-27
CA2078985C (fr) 2004-11-09
EP0522138B1 (fr) 2003-03-19

Similar Documents

Publication Publication Date Title
US6372223B1 (en) Influenza virus vaccine composition
US6635246B1 (en) Inactivated influenza virus vaccine for nasal or oral application
Eliasson et al. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine
Virelizier Host defenses against influenza virus: the role of anti-hemagglutinin antibody
KR960003378B1 (ko) 백신 제제
KR100703571B1 (ko) 인플루엔자에 대한 펩티드-기초 백신
US6485729B1 (en) Neuraminidase-supplemented compositions
Elvander et al. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses
Webster et al. Matrix protein from influenza A virus and its role in cross-protection in mice
Potter et al. A new surface-antigen-adsorbed influenza virus vaccine II. Studies in a volunteer group
US20100196495A1 (en) Delivery of flu antibodies to surfaces in contact with air
US5741493A (en) Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
US6921543B2 (en) Immunomodulatory preparation
Glück Intranasal immunization against influenza
US8287887B2 (en) Antigen-and-drug vehicle comprising synthetic peptide, and mucosal vaccine using the same
AU654699B2 (en) Influenza virus vaccine composition having a synergistic effect and containing influenza virus core as an additive
Chang et al. Single immunization with MF59-adjuvanted inactivated whole-virion H7N9 influenza vaccine provides early protection against H7N9 virus challenge in mice
Webster et al. Efficacy of equine influenza vaccines for protection against A/Equine/Jilin/89 (H3N8)—a new equine influenza virus
KR20090016659A (ko) 비로좀을 기제로 한 비강내 인플루엔자 백신
EP4316515A1 (en) Influenza vaccine
Morein et al. Immunity against parainfluenza-3 virus in cattle: anti-neuraminidase activity in serum and nasal secretion
WO1997041891A1 (en) Compositions and methods for protection against immunologically diverse isolates of influenza virus
US20150174236A1 (en) Viral vaccine and process for preparing the same
AU2001293477B2 (en) Immunomodulatory preparation
Potter et al. Immune response of mice to immunization with subunit influenza A vaccine in DTP vaccine

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired